NCT02275780View on ClinicalTrials.gov

Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)

PHASE3CompletedINTERVENTIONAL

Enrollment

769

Participants

Timeline

Start Date

December 1, 2014

Primary Completion Date

September 29, 2016

Study Completion Date

March 6, 2023

Conditions

HIV-1

Interventions

DRUG

Doravirine

Doravirine 100 mg tablet administered p.o. q.d.

DRUG

Darunavir

Darunavir 800 mg tablet administered p.o. q.d.

DRUG

Ritonavir

Ritonavir 100 mg tablet administered p.o. q.d.

DRUG

TRUVADA™ or EPZICOM™/KIVEXA™

The investigator selects either TRUVADA™, a tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate p.o. q.d. or EPZICOM™/KIVEXA™, a tablet containing 600 mg abacavir sulfate and 300 mg lamivudine, p.o. q.d.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02275780 - Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018) | Biotech Hunter | Biotech Hunter